局部切除与全直肠系膜切除在淋巴结阳性直肠癌新辅助放化疗后的倾向评分匹配分析
本回顾性研究纳入临床T2-3且淋巴结阳性(cN+)的低位直肠癌患者,接受术前放化疗(50-50.4 Gy/25-28次,联合2周期5-FU或卡培他滨)后行全直肠系膜切除(TME)或局部切除(LE)。结论提示在cN+直肠癌中,新辅助放化疗后LE的肿瘤学结局与TME相当,但可能仅适用于原发灶反应良好且淋巴结转移较小的患者。
要点
- cN+低位直肠癌新辅助放化疗后,LE与TME的3年肿瘤学结局无统计学差异。
- 该结论可能仅适用于原发灶反应良好且淋巴结转移较小的患者。
- 研究为回顾性设计,LE组仅55例,匹配后每组48例,需谨慎解读。
核心结论
- 在临床淋巴结阳性直肠癌患者中,术前放化疗后局部切除的肿瘤学结局与全直肠系膜切除相当。
- 该发现可能仅适用于原发肿瘤反应良好且淋巴结转移较小的患者。
研究设计与样本
- 回顾性研究纳入临床T2-3且cN+的低位直肠癌患者,接受术前放化疗后行TME或LE。
- 排除临床T1或T4、肿瘤距肛缘>7 cm及同时性远处转移者;淋巴结≥5 mm定义为肿瘤阳性,转移淋巴结>20 mm者排除。
- 术前放化疗为50-50.4 Gy/25-28次/5周,联合2周期5-氟尿嘧啶或口服卡培他滨。
- 采用倾向评分1:1匹配分析,比较局部无复发生存、无病生存和总生存。
临床怎么用
- 对于cN+低位直肠癌经术前放化疗后原发灶反应良好且淋巴结转移较小者,可考虑局部切除作为TME的替代选择。
- 治疗决策需结合原发灶反应和淋巴结转移大小评估,不可外推至所有cN+直肠癌患者。
局限性
- 研究为回顾性设计,LE组样本量较小(55例),匹配后每组仅48例。
- 结论可能仅适用于原发灶反应良好且淋巴结转移较小的患者,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine whether local excision (LE) outcomes were comparable to total mesorectal excision (TME) outcomes in node-positive (cN+) rectal cancer patients who were good responders. METHODS AND MATERIALS: This retrospective study included clinical T2-3 and cN+ low rectal cancer patient who received preoperative chemoradiotherapy (PCRT) followed by TME or LE. Clinical stage T1 or T4 tumors, upper-to-middle rectal tumors (>7 cm from anal verge), and synchronous distant metastases were excluded. Lymph nodes ≥5 mm in size were defined as tumor-positive, and patients with metastatic lymph nodes >20 mm in size were excluded. Preoperative chemoradiotherapy comprised radiation (50-50.4 Gy/25-28 fractions over 5 weeks) with 2 cycles of 5-fluorouracil or oral capecitabine. Propensity scores were computed from tumor and patient variables and used for 1-to-1 matched analysis. Local recurrence-free survival, disease-free survival, and overall survival were compared between the 2 matched groups. RESULTS: Between January 2007 and December 2013, 563 and 55 patients underwent TME and LE, respectively. The median follow-up period was 54 months. In propensity score-matched analysis, 48 patients were included in each group. No statistical differences were observed in 3-year local recurrence-free survival (97.9% vs 97.9%, P = .994), 3-year disease-free survival (91.5% vs 91.4%, P = .968), or 3-year OS (93.7% vs 97.9%, P = .809) between the TME and LE groups. CONCLUSIONS: In clinical N+ rectal cancer patients, oncologic outcomes of PCRT followed by LE were comparable to those of TME; this finding might be applicable only to those patients with good response in the primary tumor and small lymph node metastases.
引用
- Shin YS, Park JH, Yoon SM, et al. Total Mesorectal Excision Versus Local Excision After Preoperative Chemoradiotherapy in Rectal Cancer With Lymph Node Metastasis: A Propensity Score-Matched Analysis. Int J Radiat Oncol Biol Phys. 2018. PMID: 29678529. doi:10.1016/j.ijrobp.2018.02.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。